logo

For the Inventor, By the Inventor

Budapest, Hungary

Zoltan Kapui

This inventor holds 19 USPTO granted patents and 3 published patent applications, primarily in Pharmaceutical Chemistry. Top assignees: Sanofi-Aventis, Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt., Sanofi. Active years: 1993-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zoltan Kapui. Retrieved from https://idiyas.com/inventor/zoltan-kapui

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 

% Patents Active = 26.3

Average Co-Inventor Count = 11.6

ph-index = 4

Forward Citations = 42(Granted Patents)


Company Filing History:

goldMedal14 out of 390 
 
Sanofi-Aventis
 patents
silverMedal3 out of 283 
 
Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.
 patents
bronzeMedal2 out of 1,547 
 
Sanofi
 patents

Years Active: 1993-2013

Loading Chart...
Areas of Expertise:
Adenosine Receptor Ligands
Dipeptidyl Peptidase Inhibitors
Orexin Antagonists
Aminoquinoline Derivatives
Pyrrolidinyl Derivatives
Isoquinoline Compounds
Therapeutic Applications
Triazolo-quinolin Derivatives
Pyrimidine Derivatives
Compounds
Fluoropyrrolidines
19 patents (USPTO):Explore Patents
1. 8420636 - Pyrrolidinyl-alkyl-amide derivatives, their preparation, and their therapeutic application as CCR3 receptor ligands (2013-04-16),
2. 8338411 - Compounds (2012-12-25),
3. 8071601 - Aminoquinoline derivatives and their use as adenosine A3 ligands (2011-12-06),
4. 8063045 - Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity (2011-11-22),
5. 8044078 - Amino-alkyl amide derivatives as CCR3 receptor ligands (2011-10-25),
6. 7812031 - Pyrimidine derivatives as orexin receptor antagonists (2010-10-12),
7. 7799922 - Aminoquinoline derivatives and their use as adenosine A3 ligands (2010-09-21),
8. 7713992 - Triazolo-quinolin derivatives useful as adenosine receptor ligands (2010-05-11),
9. 7709489 - Imidazoquinoline derivatives as adenosine A3 receptor ligands (2010-05-04),
10. 7659298 - Pyrazole derivatives and use thereof as orexin receptor antagonists (2010-02-09),
11. 7655663 - Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity (2010-02-02),
12. 7652021 - Compounds useful for DPP-IV enzyme inhibition (2010-01-26),
13. 7547696 - Aminoquinoline derivatives and their use as adenosine A3 ligands (2009-06-16),
14. 7419977 - Imidazoquinoline derivatives as adenosine A3 receptor ligands (2008-09-02),
15. 7365089 - Triazolo-quinolin derivatives useful as adenosine receptor ligands (2008-04-29),

Title: Zoltan Kapui: Pioneering Innovations in Pharmaceutical Technology

Introduction:

Zoltan Kapui, a visionary inventor based in Budapest, HU, has made a significant impact in the world of technology through his passion for innovation and unwavering dedication to excellence. With over 19 patents to his name, Kapui's groundbreaking work continues to inspire the next generation of inventors and entrepreneurs.

Latest Patents:

One of Zoltan Kapui's latest patents includes the development of Pyrrolidinyl-alkyl-amide derivatives, their preparation, and their therapeutic application as CCR3 receptor ligands. These compounds hold immense potential in the field of pharmaceuticals, offering new avenues for therapeutic interventions. Additionally, Kapui has also patented adenosine A receptor ligands that demonstrate promising results as antagonists, paving the way for innovative pharmaceutical compositions.

Career Highlights:

Throughout his illustrious career, Zoltan Kapui has showcased an unparalleled commitment to pushing the boundaries of innovation. Having worked with renowned companies such as Sanofi-Aventis and Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt., Kapui has accumulated a wealth of experience in the pharmaceutical industry. His contributions have not only led to groundbreaking inventions but have also established him as a key figure in the realm of technology and healthcare.

Collaborations:

Zoltan Kapui's collaborations with esteemed colleagues such as Sandor Batori and Peter Aranyi have been instrumental in his journey towards innovation. Together, they have synergized their expertise to tackle complex challenges and drive forward pioneering solutions in pharmaceutical technology. The spirit of collaboration and shared vision has been a cornerstone of Kapui's success.

Conclusion:

Zoltan Kapui's relentless pursuit of innovation and his remarkable portfolio of patents underscore his indelible impact on the world of technology. Through his inventive spirit and collaborative efforts, Kapui continues to shape the landscape of pharmaceutical advancements, leaving a lasting legacy that resonates with aspiring inventors and entrepreneurs worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…